文献速递临床试验与 GCP真实世界研究与卫生经济

通过坚持辅助内分泌治疗改善早期乳腺癌女性结局(SWEET):一项以患者为中心的干预提高早期乳腺癌内分泌治疗依从性的实用性随机对照试验研究方案

Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET): study protocol for a pragmatic randomised control trial of a patient-centred intervention to improve adherence to endocrine therapy in early breast cancer.
PubMed 文献 · Trials · 2025-11-26

SWEET是一项英国实用性、开放标签随机对照试验,计划纳入1460例1-3期雌激素受体阳性早期乳腺癌术后、首次内分泌治疗处方14周内的女性,随机接受HT&Me干预联合常规护理或单纯常规护理。HT&Me干预包括观看动画、与SWEET研究执业者两次相隔约3个月的咨询、18个月使用交互式HT&Me网络应用及每月定期提醒。主要终点为辅助内分泌治疗依从性和癌症特异性健康相关生活质量。

要点

  • 至少5年辅助内分泌治疗可大幅降低雌激素受体阳性早期乳腺癌复发和死亡风险,但依从性欠佳。
  • SWEET试验评估HT&Me干预对改善内分泌治疗依从性和癌症特异性健康相关生活质量的有效性与成本效果。
  • HT&Me干预包含动画、两次研究执业者咨询、18个月网络应用访问及每月定期提醒。

核心结论

  • SWEET试验旨在解决乳腺癌幸存者中辅助内分泌治疗依从性欠佳这一重要问题,该试验有潜力改善生活质量和内分泌治疗依从性,减少复发和乳腺癌死亡。

研究设计与样本

  • 英国实用性、开放标签随机对照试验,计划纳入1460例1-3期雌激素受体阳性早期乳腺癌、已完成手术且首次内分泌治疗处方14周内的女性。
  • 参与者完成基线问卷后随机分配至HT&Me干预联合常规护理组或单纯常规护理组,并在6、12、18个月完成随访问卷。
  • 将开展多方法过程评估,包括探索干预作用机制的定量分析,以及对参与者和参与试验的医疗专业人员的定性访谈。

关键数值与推荐

  • 主要终点为辅助内分泌治疗依从性(结合自报药物依从性报告量表和处方兑现记录计算的天数覆盖率)和癌症特异性健康相关生活质量(癌症治疗功能评估量表-通用版)。
  • 次要终点为辅助内分泌治疗特异性健康相关生活质量及试验内成本-效用分析(评估成本效果)。
  • HT&Me干预为循证、理论指导且以患者为中心,包括观看动画、与SWEET研究执业者两次相隔约3个月的咨询、18个月使用交互式HT&Me网络应用及每月定期提醒。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 方案中已列出并解决的挑战包括:研究中心提供干预的能力、全国乳腺癌症服务的差异以及依从性测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At least 5 years of adjuvant endocrine therapy substantially reduces risks of recurrence and mortality in oestrogen-receptor positive early breast cancer. However, adherence to endocrine therapy is sub-optimal; poor adherence is associated with higher risks of recurrence and death from breast cancer, worse cancer-specific health-related quality-of-life, and increased healthcare costs. The SWEET randomised control trial aims to evaluate effectiveness and cost-effectiveness of the HT&Me intervention in reducing poor adherence to adjuvant endocrine therapy and improve cancer-specific health-related quality-of-life in women with oestrogen-receptor positive early breast cancer. METHODS: This is a UK based, pragmatic, open label randomised control trial. Participants (stages 1-3 oestrogen-receptor positive breast cancer, completed surgery, within 14 weeks of first endocrine therapy prescription; n = 1460) complete a baseline questionnaire, and are randomised to the HT&Me intervention plus usual care, or usual care alone. The HT&Me intervention is evidence-based, theory-informed and patient-centred. It consists of viewing an animation, two consultations with a SWEET study practitioner (a health care professional trained in delivering the intervention) approximately 3 months apart, access to the interactive HT&Me web-app for the 18 months, and regular monthly nudges. All participants complete follow-up questionnaires at 6, 12, and 18 months. A multi-method process evaluation will be conducted involving quantitative analysis exploring mechanisms of action of the intervention, and qualitative interviews with a sample of participants and health care professionals involved in the trial. Primary endpoints are adjuvant endocrine therapy adherence (combined self-report (Medication Adherence Report Scale) and Proportion of Days Covered calculated from prescription encashment records) and cancer-specific health-related quality-of-life (Functional Assessment of Cancer Therapy Scale- General). Secondary endpoints are adjuvant endocrine therapy-specific health-related quality-of-life and within-trial cost-utility analysis which will evaluate cost-effectiveness. DISCUSSION: The SWEET trial seeks to address a significant issue affecting the growing population of breast cancer survivors: poor adherence to adjuvant endocrine therapy. Challenges addressed and resolved within the protocol include the following: capacity at sites to deliver the intervention; variations in breast cancer services nationally; and measuring adherence. This trial has potential to improve quality of life and adherence to endocrine therapy; reducing numbers of recurrences and breast cancer deaths, benefiting women, their families and the health service. TRIAL REGISTRATION: ISRCTN Number: ISRCTN24852890 registered on 02.08.2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. McGeagh L, Walker A, Hiller L, et al. Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET): study protocol for a pragmatic randomised control trial of a patient-centred intervention to improve adherence to endocrine therapy in early breast cancer. Trials. 2025. PMID: 41299751. doi:10.1186/s13063-025-09056-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。